Abstract:Abstract Objectives Explore co-morbidity profile of persons with chronic myeloid leukemia (CML) in chronic phase receiving tyrosine kinase-inhibitor (TKI) therapy. Identify the effect of co-morbidity(ies) on response to TKI-therapy, patient-reported satisfaction with TKI-therapy, adverse impact on patients' work and daily lives and health-related quality-of life (HRQoL). Methods We distributed an anonymous, non-interventional, cross-sectional multiple choice questionnaire to ascertain common co-morbidities to adults with CML. Eligibility criteria included persons with chronic phase CML receiving TKI treatment >=3 months. Satisfaction with TKI-therapy was analyzed as: (1) high satisfaction; (2) satisfaction; (3) dissatisfaction; and (4) extreme dissatisfaction. Respondent-reported TKI-therapy-related adverse impact on work and daily life was assessed as Y/N. The SF-36 Health Survey was used to measure HRQOL and used to develop 2 summary scores of physical component summary (PCS) and mental component summary (MCS). Results Data from 1,143 respondents were analyzed. 725 (63%) were male. Median age was 42 years (range, 18-88 years). 944 (83%) started TKI-therapy <6 months after diagnosis and 868 (76%) were currently on imatinib. 742 (65%) were receiving branded TKIs drugs including Glivec®, Tasigna® and Sprycel®. Median TKI-therapy-duration was 29 months (range, 3-182 months). 878 (78%) achieved a complete cytogenetic response (CCyR) and 479 (43%), a complete molecular response (CMR). 307 (27%) had >=1 co-morbidity and 79 (7%) had >=2 co-morbidities including hypertension (30%), diabetes (21%), heart (12%), gastro-intestinal (12%) liver (12%), kidney (8%), cerebro-vascular (7%) and lung diseases (6%), thrombosis (1%), other cancer (8%) and other (15%). Increasing age (OR=2.0; 95% CI, 1.7, 2.2; p<0.001) and starting TKI treatment >6 months from diagnosis (OR=1.5; [1.0, 2.1]; p=0.040) were associated with co-morbidity(ies) in multivariate analyses. 97 respondents (32%) with co-morbidity(ies) were receiving drugs in addition to TKIs. Respondent satisfaction levels with TKI-therapy were: (1) high satisfaction, 37%; (2) satisfaction, 53%; (3) dissatisfaction, 8%; and (4) extreme dissatisfaction, 2%. 497 respondents (43%) reported TKI-therapy-related negatively impacted work and daily life. There was no significance between type of TKI, achieving CCyR or CMR and respondent satisfaction with TKI-therapy. Co-morbidity profile was significantly-associated with respondent-reported >= satisfaction with TKI-therapy: no co-morbidity, 759 (91%); cardio-cerebral vascular diseases (CCVD), metabolic syndrome and/or other cancers, 176 (93%); and other benign diseases, 99 (85%; p-value for trend=0.056). Co-morbidity profile was also significantly-associated with respondent-reported TKI-therapy-related adverse impact on work and daily life: no co-morbidity, 363 (47%); CCVD, metabolic syndrome and/or other cancers, 68 (41%); and other benign diseases, 66 (65%; p-value for trend <0.001). Co-morbidity profile was also significantly correlated with HRQoL outcomes. PCS score for each co-morbidity profile were: no co-morbidity, 47.9+/-8.7; CCVD, metabolic syndrome and/or other cancers, 44.4+/-9.8; and other benign diseases, 43.2+/-9.9; p<0.001. MCS score for each co-morbidity profile were: no co-morbidity, 49.9+/-10.9; CCVD, metabolic syndrome and/or other cancers, 52.3+/-10.7; and other benign diseases, 46.0+/-11.2; p<0.001. (Figure) Multivariate analyses showed co-morbidity profile was an independent factor affecting patients' work and daily life (OR=1.4; [1.4-1.9]; p=0.008), PCS (OR=1.4; [1.2-1.7]; p=0.001) and MCS (OR=1.5; [1.2-1.9]; p=0.002). Conclusions The survey showed that 27% (24, 29%) of persons with chronic phase CML receiving TKI-therapy had co-morbidity(ies). CCVD and/or metabolic syndrome were the most common. Co-morbidity(ies) were more common in older subjects. Co-morbidity profile significantly influenced patients' work, daily life and HRQoL. Assessing co-morbidity profile in persons with CML is important to identify persons needing improvement of quality-of-care and HRQoL. Figure 1 Satisfaction, adverse impact on work and daily life by co-morbidity profile Figure 1. Satisfaction, adverse impact on work and daily life by co-morbidity profile Figure 2 Health-related quality of life by co-morbidity profile Figure 2. Health-related quality of life by co-morbidity profile Disclosures No relevant conflicts of interest to declare.

Variables Associated with Self-Reported Anxiety and Depression Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.

[Study on Anxiety and Depressive Disorder of Inpatients in General Hospital].

Health-related Quality of Life in Children with Chronic Myeloid Leukemia in the Chronic Phase

Comorbidity Profile and Its Impact on Reported Outcome in Chinese Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Tyrosine Kinase-Inhibitor Therapy

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

[Patient Reported Outcome of Tyrosine Kinase Inhibitor Related Side Effects and Their Impact on Daily Life in Chinese Patients with Chronic Myeloid Leukemia in the Chronic Phase].

A Survey on Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia in China: from Patients' Perspective

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Prevalence, risk factors, and prognostic value of anxiety and depression in acute myeloid leukemia

[Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].

Variables Associated with Patient-Reported Outcomes in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services

Impact of Socio-Demographic Co-Variates on Prognosis, Tyrosine Kinase-Inhibitor Use and Outcomes in Persons with Newly-Diagnosed Chronic Myeloid Leukaemia

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy

Higher Out-of-pocket Expenses for Tyrosine Kinase-Inhibitor Therapy is Associated with Worse Health-Related Quality-of-life in Persons with Chronic Myeloid Leukemia

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

Combination of Socio-Demographic and Clinical Co-Variates for Predicting Treatment Responses and Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events

[Severe Hematologic Toxicity and Its Impact on Treatment Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy].